WebDoctor Encyclopedia

Genitourinary

Urothelial Carcinoma of the Bladder

Urothelial carcinoma is the most common type of bladder cancer. This entry covers its appearance, warning signs such as blood in the urine, staging, and treatment from TURBT to immunotherapy.

Medically reviewed Last reviewed October 21, 2026

Introduction

Urothelial carcinoma (UC), historically referred to as transitional cell carcinoma (TCC), is the most prevalent malignancy of the urinary tract, accounting for approximately 90–95% of all bladder cancers in Western countries. It arises from the urothelium, a specialized stratified epithelium lining the renal pelvis, ureters, bladder, and proximal urethra. While the bladder is the most common site, the disease is fundamentally a “field effect” malignancy, meaning the entire urothelial lining is at risk for synchronous or metachronous tumors.

Epidemiology and Risk Factors

Bladder cancer is the 10th most common cancer worldwide and the 4th most common in men. There is a significant gender disparity, with a male-to-female ratio of approximately 3:1 to 4:1, though women often present at a more advanced stage and have worse survival outcomes stage-for-stage. The median age at diagnosis is 73 years; it is rare before age 40.

Major Risk Factors

Risk Factor Mechanism / Details Relative Risk
Tobacco Smoking Single most important risk factor (~50% of cases). Aromatic amines (e.g., 2-naphthylamine, 4-aminobiphenyl) are carcinogens concentrated in urine. Risk is dose-dependent (pack-years) and persists for decades after cessation. 3x – 4x (Current smokers)
Occupational Exposure Aromatic amines, polycyclic aromatic hydrocarbons (PAHs), diesel exhaust. High-risk industries: dye, rubber, leather, textile, paint, printing, aluminum production, truck driving. Latency period: 10–40 years. 2x – 5x (Specific chemicals)
Chemotherapy (Cyclophosphamide/Ifosfamide) Metabolites (acrolein, phosphoramide mustard) are excreted in urine, causing hemorrhagic cystitis and DNA damage. Risk correlates with cumulative dose. 4x – 9x
Radiation Therapy Pelvic radiotherapy for cervical, prostate, or rectal cancer increases risk after 10+ years latency. 1.5x – 2.5x
Chronic Inflammation/Infection Chronic indwelling catheters, recurrent UTIs, bladder stones, schistosomiasis (S. haematobium – causes squamous cell carcinoma predominantly, but UC also increased). Variable
Arsenic in Drinking Water High levels (>300 µg/L) linked to skin, lung, and bladder cancer. Dose-dependent
Genetic Susceptibility GST (glutathione S-transferase) null genotypes (impaired detoxification), NAT2 slow acetylator phenotype. Lynch syndrome (HNPCC) increases UC risk (upper tract > bladder). Modest increase

Protective Factors

  • High fluid intake: Dilutes urinary carcinogens, reduces contact time.
  • Fruit/Vegetable consumption: Antioxidants (vitamins A, C, E, carotenoids).
  • Smoking cessation: Risk decreases by ~30% within 1–4 years, approaching never-smokers after 20+ years.

Pathophysiology and Molecular Pathways

Urothelial carcinogenesis follows two distinct molecular pathways, which correlate with histologic grade, stage, and clinical behavior.

1. Non-Muscle Invasive (NMIBC) / “Papillary” Pathway (Low Grade)

  • Driver Mutations: Activating mutations in FGFR3 (Fibroblast Growth Factor Receptor 3) (~60–70% of low-grade tumors), HRAS, KRAS, PIK3CA.
  • Mechanism: These mutations promote cell proliferation and survival via the MAPK/ERK and PI3K/AKT pathways without disrupting genomic stability.
  • Chromosomal Profile: Generally diploid or near-diploid; few chromosomal losses.
  • Clinical Behavior: Papillary growth (exophytic), high recurrence rate (50–70%), low progression rate to muscle invasion (<10–15%).

2. Muscle-Invasive (MIBC) / “Solid” Pathway (High Grade)

  • Driver Alterations: Loss of function mutations in TP53 (~50–70%), RB1 (Retinoblastoma), PTEN. TERT promoter mutations are near-universal (~80%) in both pathways, driving immortality.
  • Mechanism: Genomic instability, aneuploidy, chromosomal gains/losses (loss of 9q, 9p, 8p, 11p, 17p, 13q).
  • Clinical Behavior: Sessile/flat growth (endophytic), high potential for invasion, lymphovascular invasion (LVI), and metastasis.

Molecular Subtypes of MIBC (Consensus Classification)

Recent genomic profiling (TCGA, Lund, Baylor, MDA) identifies distinct subtypes with prognostic and predictive implications:

The international consensus classification of muscle-invasive bladder cancer recognises six molecular subtypes.

Subtype Main features Behaviour
Luminal papillary FGFR3 changes, papillary growth. Best outlook; often lower response to chemotherapy.
Luminal non-specified Luminal genes with stromal and immune cells. Intermediate.
Luminal unstable Genomic instability, cell-cycle activity. Intermediate.
Stroma-rich Abundant stroma and immune cells. Intermediate.
Basal/squamous TP53/RB1 loss, squamous features. Aggressive; may respond well to cisplatin chemotherapy.
Neuroendocrine-like Neuroendocrine genes, TP53/RB1 loss. Rare; poorest outlook.

Clinical Presentation: Symptoms

The clinical presentation of urothelial carcinoma is often nonspecific. The hallmark symptom is hematuria, but irritative voiding symptoms are common, particularly with carcinoma in situ (CIS) or high-grade tumors.

1. Hematuria (Blood in Urine)

  • Gross (Macroscopic) Hematuria: Visible to the naked eye (pink, red, cola-colored). Present in 75–85% of patients at diagnosis.
    • Characteristics: Usually painless, intermittent, and often self-limiting (stops spontaneously), leading to dangerous delays in presentation. It may occur only once.
    • Clots: Passage of clots suggests larger tumor burden or bleeding diathesis; clots can cause acute urinary retention.
  • Microscopic Hematuria: >3 red blood cells (RBCs) per high-power field (HPF) on urinalysis in the absence of infection. Found in ~10–15% of asymptomatic adults; bladder cancer prevalence in this group is ~2–5% (higher in smokers >35 years).

2. Irritative Voiding Symptoms (Storage Symptoms)

Often mimic urinary tract infection (UTI) or overactive bladder (OAB). Caused by tumor inflammation, CIS (flat high-grade lesion), or trigone involvement.

Symptom Description
Frequency Passing urine more than 8 times a day.
Urgency Sudden need to pass urine that is hard to delay.
Nocturia Waking 2 or more times a night to pass urine.
Dysuria Burning or pain on passing urine.
Warning sign Symptoms that persist after antibiotics, or white cells without infection (sterile pyuria), may point to CIS.

3. Obstructive Voiding Symptoms

Indicate locally advanced disease (T3/T4) or large tumor burden at bladder neck/prostatic urethra.

  • Weak stream, hesitancy, straining, incomplete emptying, post-void dribbling.
  • Acute urinary retention (rare initial presentation).

4. Symptoms of Advanced/Metastatic Disease

Symptom Likely cause
Flank pain Blocked ureter causing kidney swelling.
Pelvic mass Advanced local tumour.
Leg swelling Blocked pelvic veins or lymphatics.
Bone pain Spread to spine, pelvis or femur.
Cough, breathlessness, coughing blood Lung metastases.
Weight loss, fatigue Advanced disease.
Paraneoplastic syndromes Rare: blood clots, hypertrophic osteoarthropathy.

Summary of Symptom Urgency

Symptom Complex Typical Associated Stage Action Required
Painless Gross Hematuria Any (Ta to T4) Urgent Urology Referral (2-week wait pathway)
Persistent Microscopic Hematuria (>35 yrs, smoker) Ta, T1, CIS Urgent Urology Referral
Refractory Irritative Symptoms (Sterile pyuria) CIS, High-grade T1 Urgent Urology Referral
Flank Pain + Hematuria T2-T4 (Ureteral obstruction) Emergent Imaging + Urology
Constitutional + Bone Pain Metastatic (M1) Oncology Referral + Staging

How Does It Look: Gross and Microscopic Appearance

Understanding the visual and histologic appearance is critical for risk stratification and treatment planning.

A. Gross Appearance (Cystoscopic & Surgical View)

During cystoscopy (the gold standard for diagnosis), tumors are described by morphology, number, size, location, and appearance of the base.

1. Papillary (Exophytic) Tumors – Non-Muscle Invasive (Ta, Low/High Grade)

  • Appearance: Frond-like, “sea anemone” or “cauliflower” projections floating freely in the bladder lumen. Attached by a narrow stalk (pedunculated) or broad base (sessile).
  • Color: Pink to red, vascular, often bleed easily on touch (friable).
  • Surface: May have fibrin deposition or necrosis on tips.
  • Significance: Confined to mucosa (Ta) or lamina propria (T1). Multiple tumors common (multifocality).

2. Sessile / Solid / Nodular Tumors – Muscle-Invasive (T2-T4) or High-Grade T1

  • Appearance: Broad-based, flat or slightly raised, firm masses arising from the bladder wall. No distinct stalk.
  • Color: Often paler, grey-white, or yellowish (necrosis) compared to papillary tumors. Less vascular on surface but deeply invasive.
  • Consistency: Firm, gritty, or “rock-hard” on palpation (resectoscope loop or bimanual exam under anesthesia).
  • Significance: High suspicion for muscularis propria invasion (T2+).

3. Carcinoma In Situ (CIS) – High-Grade Flat Lesion (Tis)

  • Appearance: Deceptively subtle. Flat, velvety, erythematous (red), granular, or “angry-looking” mucosa.
  • Key Feature: Loss of normal vascular pattern (avascular areas) or abnormal “corkscrew” vessels. May look like cystitis, hunter’s lesion, or radiation cystitis.
  • Detection: Requires high-definition white light, Narrow Band Imaging (NBI), Photodynamic Diagnosis (PDD / Blue Light Cystoscopy) with Hexaminolevulinate (HAL), or random biopsies of normal-appearing mucosa.
  • Significance: High-grade, non-invasive but high progression risk (50–80% to MIBC if untreated). Often multifocal.

4. Variant Histology (Gross Clues)

  • Squamous Differentiation: Often large, necrotic, ulcerated, infiltrative masses.
  • Micropapillary: Small, fragile papillae; high risk of LVI.
  • Plasmacytoid/Signet Ring: Diffuse wall thickening (“leather bottle” bladder), minimal mucosal abnormality, often missed on standard biopsy.
  • Sarcomatoid: Fleshy, polypoid, highly vascular, mimics sarcoma.

B. Microscopic Appearance (Histopathology)

Diagnosis and grading rely on the WHO 2022 Classification (replacing 1973/2004 systems) and TNM Staging (AJCC 8th Ed.).

WHO 2022 Grading System (Two-Tiered)

Grade Former Terminology Architectural Features Cytologic Features Clinical Behavior
Low-Grade (LGUC) Papillary Neoplasm of Low Malignant Potential (PUNLMP) / Low Grade Orderly, papillary fronds; thin fibrovascular cores; polarity maintained. Minimal atypia; uniform nuclei; inconspicuous nucleoli; low mitotic rate (apical only). Recurrent (50-70%), Rarely progresses to MIBC (<5-10%).
High-Grade (HGUC) High Grade / Carcinoma In Situ (CIS) Disorderly architecture; fused papillae, solid nests, cribriform, micropapillary; loss of polarity. Marked atypia: Pleomorphism, hyperchromasia, prominent nucleoli, loss of polarity, abnormal mitoses (throughout thickness). High recurrence, High progression risk (30-50% to MIBC). CIS is by definition High-Grade.

Key Histologic Features for Staging (Depth of Invasion)

  • Urothelium (Mucosa): Normal thickness 3-7 cells.
  • Lamina Propria (LP): Loose connective tissue, blood vessels, lymphatics, muscularis mucosae (thin smooth muscle bundles – NOT muscularis propria).
  • Muscularis Propria (Detrusor Muscle – MP): Thick, interlacing smooth muscle bundles (inner longitudinal, middle circular, outer longitudinal).
  • Perivesical Fat: Adipose tissue outside bladder wall.
Stage Depth of Invasion Histologic Landmark
Ta Confined to urothelium No LP invasion.
Tis (CIS) Confined to urothelium Full-thickness high-grade atypia, flat.
T1 Invades Lamina Propria Tumor cells breach basement membrane into LP. Critical substaging: T1a (superficial LP) vs T1b (deep LP / muscularis mucosae) vs T1c (with LVI) – impacts prognosis.
T2 Invades Muscularis Propria T2a: Superficial half (inner). T2b: Deep half (outer).
T3 Invades Perivesical Fat T3a: Microscopic. T3b: Macroscopic (extravesical mass).
T4 Invades Adjacent Organs T4a: Prostate, uterus, vagina. T4b: Pelvic/abdominal wall.

Variant Histologies (WHO 2022) – Must be reported if >10-20% component

Variant Features Clinical impact
Nested, microcystic, micropapillary Bland-looking but invasive; frequent vessel invasion. Often understaged on biopsy; aggressive.
Sarcomatoid Mixed carcinoma and spindle cells. Poor outlook; chemo-resistant.
Plasmacytoid / signet ring Diffuse spread, E-cadherin loss; mimics lymphoma. Very poor outlook.
Lymphoepithelioma-like Dense immune infiltrate. May respond better to immunotherapy.
Squamous or glandular differentiation Mixed with urothelial carcinoma. May respond less to cisplatin.

Diagnostic Workup

1. Initial Evaluation (Primary Care / Emergency)

Step What it checks
History Smoking, workplace chemicals, cyclophosphamide, visible or hidden blood in urine, other symptoms.
Examination Abdominal or pelvic mass, bimanual exam, lymph nodes.
Urine tests Dipstick, microscopy and culture; treat infection first, then recheck.
Kidney function Creatinine and eGFR, for contrast scans and cisplatin eligibility.
Urine cytology Very specific (over 95%) for high-grade cancer and CIS; misses most low-grade tumours.

2. Urine Biomarkers (Adjuncts to Cytology/Cystoscopy)

Used to reduce cystoscopy frequency in surveillance or triage hematuria.

Test What it detects Strengths / limits
UroVysion FISH Chromosome 3, 7, 17 gains and 9p21 loss. Good for high-grade; weak for low-grade.
NMP22 / BladderChek Nuclear matrix protein. Quick, but false positives with inflammation or stones.
Cxbladder Urine mRNA panel. High negative predictive value (good for ruling out).
Xpert Bladder Cancer Monitor Urine mRNA panel. Used in follow-up.

None of these replaces cystoscopy, which remains the standard test for blood in the urine.

3. Cystoscopy (Gold Standard)

  • Flexible Cystoscopy (Office): Diagnostic, under local anesthetic gel. Assesses number, size, location, appearance, prostatic urethra (in men).
  • Rigid Cystoscopy / TURBT (Operating Room): Under spinal/general anesthesia. Allows resection (TURBT) for diagnosis AND treatment. Bimanual exam under anesthesia (EUA) essential for clinical staging (T2 vs T3/T4).

4. Imaging (Staging)

Modality Indication Details
CT Urography (CTU) Standard for all new diagnoses. Triple phase (non-contrast, nephrographic, excretory). Evaluates upper tracts (UC field effect), bladder wall thickening, nodes, liver, lungs, bones.
MRI Pelvis Problem-solving / Local Staging Superior soft tissue contrast for T2 vs T3 distinction, rectal/vaginal/prostate invasion. No radiation. Used if CT contraindicated (allergy, pregnancy, renal failure).
Chest CT Staging MIBC / High-risk NMIBC Baseline for metastatic workup.
Bone Scan / PET-CT Symptomatic / Alkaline Phosphatase ↑ / Clinical M1 PET-CT (FDG) limited by urinary excretion; PSMA-PET or F-18 FDG PET/MRI emerging for nodal/metastatic detection.

5. Transurethral Resection of Bladder Tumor (TURBT) – Diagnostic & Therapeutic

Technique Purpose / details
Standard TURBT Remove all visible tumour, including bladder muscle in the sample.
En bloc resection Removes the tumour in one piece for better staging.
Blue-light cystoscopy HAL instilled 1 hour before; finds about 20–25% more CIS and small tumours.
Narrow band imaging Light filter highlights blood vessels; no instillation needed.
Repeat TURBT At 2–6 weeks after incomplete resection, no muscle in the sample, T1 or extensive high-grade Ta disease (residual tumour in up to half).

Staging and Risk Stratification

TNM Staging (AJCC 8th Edition / UICC 8th)

  • T (Primary Tumor): Ta, Tis, T1, T2a, T2b, T3a, T3b, T4a, T4b.
  • N (Regional Nodes): N0, N1 (single ≤2cm), N2 (single >2cm or multiple ≤5cm), N3 (>5cm or common iliac).
  • M (Distant Metastasis): M0, M1a (non-regional nodes), M1b (visceral/bone).

Risk Stratification for NMIBC (Ta, T1, CIS) – EAU / AUA Guidelines

Determines adjuvant intravesical therapy and surveillance intensity.

Risk Group Criteria (Any One) Recurrence Risk (5yr) Progression Risk (5yr) Standard Adjuvant Therapy
Low Single, Primary, Ta, LG, <3cm, No CIS ~15% <1% Single immediate post-op instillation (Mitomycin C/Gemcitabine/Epirubicin) within 6-24 hrs. No maintenance.
Intermediate Multiple / Recurrent / >3cm / Ta HG / T1 LG (rare) / (No CIS) 30–50% 5–15% Induction + 1 Year Maintenance BCG (preferred) or Chemo (MMC/Gem).
High T1 HG / CIS / Variant Histology / LVI / Prostatic Urethra / Multiple LG Ta (recurrent) + HG 50–70% 20–50% Induction + 1–3 Years Maintenance BCG (Gold Standard). Early Cystectomy discussion for highest risk (T1HG + CIS + LVI + Variant).
Very High T1HG with CIS + LVI + Variant / Failed BCG >70% >50% Radical Cystectomy strongly recommended upfront. Clinical trials.

Scoring Systems: EORTC Risk Tables (Recurrence/Progression scores 0–23 / 0–23) and CUETO (for BCG-treated patients) provide individualized probabilities.

Treatment Algorithms

A. Non-Muscle Invasive Bladder Cancer (NMIBC)

1. Transurethral Resection (TURBT)

  • Curative for Low/Intermediate risk if complete.
  • Immediate Single Post-Operative Instillation (within 24h): Reduces recurrence by ~40% (abrogates implantation of tumor cells). Contraindicated if perforation suspected or extensive resection.

2. Intravesical Therapy (Instilled via Catheter)

Agent Mechanism Schedule (Maintenance) Key Indications Major Side Effects
BCG (Live Attenuated Mycobacterium bovis) Immunotherapy: Local Th1 cytokine response (IL-2, IFN-γ, TNF-α), attracts immune cells. Induction: Weekly x 6 weeks.
Maintenance (SWOG): 3 weekly doses at 3, 6, 12, 18, 24, 30, 36 mo.
High Risk NMIBC (T1, CIS, HG Ta). Gold standard. Cystitis (90%), Flu-like (50%), Hematuria.
Serious: BCG-osis (sepsis), Granulomatous hepatitis/pneumonitis, Reactive arthritis. Contraindicated: Immunosuppression, Active TB, Gross Hematuria, Traumatic Catheterization.
Mitomycin C (MMC) Chemotherapy: Alkylating agent, DNA crosslinking. Induction 6-8wk + Monthly x 1yr (or varied). Low/Intermediate risk. Adjuvant immediate post-TURBT. Chemical cystitis, rash (hands/genitals), neutropenia (rare systemic absorption).
Gemcitabine Antimetabolite (pyrimidine analog). Weekly x 6 + Monthly maintenance. BCG-Unresponsive (FDA approved), Intermediate risk (off-label). Well tolerated. Chemical cystitis, flu-like. No systemic absorption.
Docetaxel / Valrubicin Chemo agents. Variable. BCG-Unresponsive (Valrubicin FDA approved for CIS). Local irritation.

3. BCG-Unresponsive Disease (High Unmet Need)

BCG-unresponsive means high-grade disease persists or returns within 6 months (CIS) or 12 months (Ta/T1) of adequate BCG. Radical cystectomy remains the standard; bladder-sparing options include:

Option Type Response
Pembrolizumab Intravenous PD-1 immunotherapy (approved for CIS). About 40% complete response.
Nadofaragene firadenovec Gene therapy into the bladder (interferon gene). About 50% complete response at 3 months.
Nogapendekin alfa (N-803) + BCG IL-15 agonist with BCG. About 70% complete response in CIS.
Gemcitabine + docetaxel Sequential chemotherapy into the bladder (off-label). High response rates in studies.
Chemohyperthermia Mitomycin C heated to 43 °C. Heat boosts drug effect.

4. Surveillance (Post-TURBT / Post-BCG)

  • Low Risk: Cystoscopy at 3mo, then 9mo, then annually x 5yrs. (CTU at 1-3yrs).
  • Intermediate Risk: Cystoscopy 3mo, then q3-6mo x 2yrs, q6-12mo x 3yrs, then annually. Cytology optional.
  • High Risk: Cystoscopy + Cytology q3mo x 2yrs, q6mo x 3yrs, then annually. CTU annually x 5yrs (upper tract surveillance).
  • Upper Tract Imaging: CTU preferred (detects UTUC in 2-4% of bladder UC patients).

B. Muscle-Invasive Bladder Cancer (MIBC) – cT2-T4a, N0, M0

Curative Intent is the Goal. Multidisciplinary Tumor Board (MDT) discussion mandatory.

1. Neoadjuvant Chemotherapy (NAC) + Radical Cystectomy (RC) – Standard of Care

Aspect Details
Evidence SWOG 8710, BA06 and meta-analysis: 5–8% absolute survival gain at 5 years.
ddMVAC Every 2 weeks for up to 6 cycles with G-CSF; for fit patients; higher complete response.
Gemcitabine + cisplatin Every 3 weeks for 4 cycles; better tolerated alternative.
Cisplatin eligibility eGFR over 60 (some accept 50), good performance status, no major neuropathy, hearing loss or heart failure.
If ineligible Cystectomy or radiotherapy directly; adjuvant nivolumab or chemotherapy for pT3–4 or node-positive disease.

2. Radical Cystectomy (RC) with Urinary Diversion

  • Procedure: En bloc removal of bladder, prostate + seminal vesicles (men), uterus/ovaries/fallopian tubes/anterior vaginal wall (women), pelvic lymph node dissection (PLND – template: external/internal iliac, obturator, common iliac, presacral).
  • Approaches: Open, Laparoscopic, Robotic (RARC). RARC: Less blood loss, shorter stay, similar oncologic outcomes (RAZOR, iROC trials).
  • Enhanced Recovery After Surgery (ERAS): Standard protocol (pre-op carb loading, no bowel prep, early feeding/mobilization, multimodal analgesia).

3. Urinary Diversion Options (Post-Cystectomy)

Diversion Type Description Advantages Disadvantages / Complications
Ileal Conduit (Incontinent) 15-20cm ileum → ureters anastomosed → stoma on R abdomen. External bag. Simplest, shortest OR time, lowest metabolic complications, robust. Standard for elderly/comorbid. Stoma care, body image, appliance leakage, parastomal hernia (20-30%), stenosis.
Orthotopic Neobladder (Continent) 40-60cm ileum/colon → reservoir → anastomosed to urethra. Voiding by Valsalva/Crèdea. No stoma, body image preserved, daytime continence ~85-90% (men), night ~70%. Longer OR, metabolic acidosis (Cl⁻ absorption), B12 deficiency (ileal resection), Night incontinence, Hypercontinence (retention) requiring CIC. Requires good renal function (CrCl >50), manual dexterity, cognitive function.
Continent Cutaneous Diversion (Indiana Pouch / Mainz II) Reservoir → continent stoma (cecal/appendiceal valve) → Catheterized q4-6h. No external bag, continent. Good for patients unfit for neobladder (urethral disease, sphincter incompetence). Stoma stenosis, catheterization difficulty, metabolic issues, pouch stones.

4. Trimodal Therapy (TMT) – Bladder Preservation

  • Selection Criteria (RTOG/BC2001): Solitary tumor <5cm, T2-T3a, N0, No CIS (or eradicated), No hydronephrosis, Good bladder capacity/compliance, Complete TURBT (Visually complete resection).
  • Protocol: Maximal TURBT → Concurrent Chemoradiation (Radiation 55-65 Gy + Radiosensitizer: Cisplatin 70mg/m² q3wk or 5-FU/Mitomycin C or Gemcitabine).
  • Outcomes: 5-yr OS ~50-60% (comparable to RC in selected pts). Intact bladder survival ~40-50%. Salvage RC for failure (~25-30%).
  • Mandatory: Rigid surveillance (Cystoscopy q3mo x 2yrs).

C. Metastatic / Advanced Urothelial Carcinoma (mUC)

1. First-Line Systemic Therapy

Patient group Treatment Key point
All suitable patients Enfortumab vedotin + pembrolizumab. EV-302: about halved risk of death vs chemotherapy; now preferred first line.
Cisplatin-eligible (if EV unsuitable) Gemcitabine + cisplatin (or ddMVAC), then avelumab maintenance if no progression. JAVELIN Bladder 100: longer survival (HR 0.69). Nivolumab + GC is another option.
Cisplatin-ineligible Gemcitabine + carboplatin, then avelumab maintenance. Less effective than cisplatin.
Platinum-ineligible Pembrolizumab or atezolizumab alone. Limited to patients unable to have any platinum.

2. Subsequent Lines (Post-Platinum / Post-IO)

Treatment Target / type Use Notes
Enfortumab vedotin Nectin-4 antibody-drug conjugate. After platinum and immunotherapy if not used first line (EV-301 survival gain). Rash, neuropathy, high blood sugar.
Sacituzumab govitecan Trop-2 antibody-drug conjugate. Later lines in some regions. TROPiCS-04 showed no survival gain; US approval withdrawn.
Erdafitinib FGFR inhibitor. FGFR3-altered tumours after prior therapy. High phosphate, eye (retinal) effects.
Immunotherapy Pembrolizumab, nivolumab. After platinum if not given before. —
Chemotherapy Paclitaxel, docetaxel, vinflunine (EU). Later lines. Modest benefit.

3. Palliative & Supportive Care

  • Radiation: Hematuria control, painful bone mets, spinal cord compression, obstructive uropathy (stent/nephrostomy + RT).
  • Bone Health: Denosumab/Zoledronic acid for bone mets.
  • Pain Management: WHO ladder, interventional blocks.
  • Advance Care Planning: Early goals-of-care discussions.

Follow-Up and Survivorship

Post-Cystectomy Surveillance (High Risk for Recurrence)

Test Schedule / purpose
CT chest, abdomen, pelvis Every 6 months for 2–3 years, then yearly to 5 years.
Blood tests Every 3–6 months: kidney and liver function, electrolytes, acid balance; yearly B12 after urinary diversion.
Urine cytology Detects urethral or upper-tract recurrence.
Urethral checks Every 6–12 months if at risk (recurrence 5–10%).
Upper tract imaging CT urogram yearly (2–5% risk).

Quality of Life (QoL) Issues

Issue Details and management
Sexual function Erectile dysfunction, dry orgasm; vaginal shortening or dryness. Early referral to sexual health services.
Stoma / neobladder Leakage, skin irritation, hernia, stones, self-catheterisation.
Kidney function Gradual decline; nephrology input if chronic kidney disease.
Metabolic acidosis Bowel segment absorbs acid; treat with bicarbonate or citrate.
Mental health Anxiety, depression, body image; screening and psycho-oncology.

Prevention and Early Detection

Primary Prevention

  1. Smoking Cessation: Single most effective intervention. Offer pharmacotherapy (Varenicline, NRT, Bupropion) + counseling.
  2. Occupational Safety: PPE, engineering controls, biomonitoring (adducts), regulation compliance (OSHA/EU directives).
  3. Hydration: >2.5L/day water intake.
  4. Diet: Mediterranean diet, cruciferous vegetables (isothiocyanates).

Secondary Prevention (Screening)

Group Screening advice
General population Not recommended; no proven survival benefit.
Lynch syndrome (MSH2/MSH6) Consider from age 30–35 with urine tests and/or cystoscopy.
Prior cyclophosphamide or pelvic radiotherapy Consider from about 10 years after exposure.
Occupational exposure Guidance varies by country.

Emerging Horizons and Future Directions

Area Current status
ctDNA blood tests Detect residual disease after cystectomy months before scans; IMvigor011 showed ctDNA-guided adjuvant atezolizumab improves survival.
Perioperative immunotherapy Adjuvant nivolumab (CheckMate 274) improves disease-free survival; NIAGARA (durvalumab + chemotherapy) and KEYNOTE-905 (EV + pembrolizumab) improved survival.
New immune targets TGF-beta, LAG-3, TIGIT, T-cell engagers in trials.
Molecular subtyping May guide chemotherapy and FGFR or HER2 targeting.
AI Digital pathology and radiomics for grading and response prediction.

Frequently Asked Questions (FAQ)

Q: Is bladder cancer curable? A: Yes, highly curable if caught early.

Non-muscle invasive (NMIBC) 5-year survival is >90%. Muscle-invasive (MIBC) 5-year survival is ~50-65% with aggressive treatment (Chemo + Surgery or TMT). Metastatic disease is generally incurable but treatable, with median survival now extending to 2-3+ years with new agents (EV+Pembro, Maintenance Avelumab).

Q: Will I need a stoma bag if my bladder is removed? A: Not necessarily.

You have three main options: Ileal Conduit (stoma bag), Orthotopic Neobladder (void via urethra), or Continent Cutaneous Diversion (catheterize a stoma). The choice depends on age, renal function, manual dexterity, tumor location (urethral margin), and patient preference. Discuss thoroughly with your surgeon and stoma nurse before surgery.

Q: Does BCG therapy cause tuberculosis? A: BCG is a live attenuated strain of Mycobacterium bovis.

It is not tuberculosis (M. tuberculosis). It stimulates the immune system.

Serious systemic infection (BCG-osis) is rare (<1%) but requires immediate multi-drug anti-tuberculous therapy. Standard TB tests (PPD, Quantiferon) will turn positive during/after BCG.

Q: Can I still get bladder cancer if I never smoked? A: Yes.

While smoking causes ~50% of cases, other factors include occupational chemicals, genetics (Lynch syndrome), chronic inflammation, prior chemo/radiation, and arsenic exposure. Some cases have no identifiable risk factor (“sporadic”).

Q: What does “BCG-Unresponsive” mean? A: It is a specific high-risk category defined by the FDA/EMA: High-grade recurrence (CIS or Ta/T1) after adequate

BCG therapy (at least 5 of 6 induction doses + at least 2 of 3 maintenance doses). It signals that the tumor has escaped BCG’s immune mechanism. Radical cystectomy is the gold standard cure; bladder-preserving clinical trials or newer FDA-approved agents (Pembrolizumab, Nadofaragene, Anktiva) are alternatives for those refusing/unfit for surgery.

Glossary of Key Terms

Term Meaning
CIS (Tis) Flat, high-grade cancer confined to the bladder lining.
Cystectomy Removal of the bladder (radical: with nearby organs and nodes).
ctDNA Tumour DNA in the blood; used to detect residual disease.
DFS Disease-free survival: time without signs of cancer.
GemCis Gemcitabine + cisplatin.
HR Hazard ratio; below 1 favours the treatment.
Intravesical Given into the bladder through a catheter.
LVI Lymphovascular invasion; tumour in vessels, a poor sign.
MRD Minimal residual disease after treatment.
Muscularis propria Bladder muscle wall; invasion means T2.
NAC Neoadjuvant chemotherapy, given before surgery.
NMIBC / MIBC Non-muscle-invasive / muscle-invasive bladder cancer.
ORR Objective response rate (complete + partial).
OS Overall survival.
pT0 No tumour left in the removed bladder.
PLND Pelvic lymph node dissection.
TURBT Transurethral resection of bladder tumour.
UTUC Upper tract urothelial carcinoma (kidney pelvis or ureter).
Variant histology Non-pure urothelial patterns, often more aggressive.

References (Harvard Style)

  1. Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E.M., Hernández, V., Kaasinen, E., Palou, J., Rouprêt, M., van Rhijn, B.W.G., Shariat, S.F., Soukup, V., Sylvester, R.J. and Zigeuner, R. (2022) ‘European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ)’, European Urology, 82(3), pp. 241–261. Available at: https://doi.org/10.1016/j.eururo.2022.03.010.

  2. Witjes, J.A., Bruins, H.M., Cathomas, R., Compérat, E.M., Cowan, N.C., Gakis, G., Hernández, V., Espinós, E.H., Kamat, A.M., Kersting, S., Klümpen, H.J., Lam, T.B., Lewin, S., Malmström, P.-U., Van der Meijden, A.P.M., Van Rhijn, B.W.G., Rouprêt, M., Shariat, S.F., Sylvester, R.J. and van der Kwast, T.H. (2023) ‘European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer’, European Urology, 83(3), pp. 237–260. Available at: https://doi.org/10.1016/j.eururo.2022.11.012.

  3. National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bladder Cancer. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (Accessed: October 2026).

  4. Kamat, A.M., Hahn, N.M., Efstathiou, J.A., Lerner, S.P., Malmström, P.-U., Choi, W., Dickinson, M., Daneshmand, S., Tangen, C.M., Palou Redorta, J., Syed, J.S., Sfakianos, J.P., Lamm, D.L., Chang, S.S., Boorjian, S.A., Groshen, S., Skinner, E.C., Wood, D.P. and members of the Bladder Cancer Think Tank (2021) ‘Bladder cancer’, The Lancet, 398(10311), pp. 1565–1580. Available at: https://doi.org/10.1016/S0140-6736(21)00912-6.

  5. Powles, T., Park, S.H., Voog, E., Caserta, C., Valderrama, B.P., Gürmen, K., Radulovic, S., Mori, K., De Santis, M., Lee, J.L., Melichar, B., Bono, P., Necchi, A., Lipatov, O., Hong, M.-H., Vuky, J., Rivers, B., Usari, T., Behera, M., Omilian, A., O’Neil, B., Sabbatini, R., Vogelzang, N.J., Petrylak, D.P., Bellmunt, J., on behalf of the JAVELIN Bladder 100 Investigators (2021) ‘Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma’, New England Journal of Medicine, 384(13), pp. 1212–1223. Available at: https://doi.org/10.1056/NEJMoa2031240.

  6. Rosenberg, J.E., O’Donnell, P.H., Balar, A.V., McGregor, B., Loriot, Y., Necchi, A., Dawson, N., van der Heijden, M.S., Lee, J.L., Grivas, P., Joseph, R., Dreicer, R., Vogelzang, N.J., Hoffman-Censits, J., Quinn, D.I., Sridhar, S.S., Quinn, G., Pal, S.K., Milowsky, M.I., Choueiri, T.K., Yu, E.Y., Hahn, N.M., Agarwal, N., Vaishampayan, U.N., Hahn, A.W., Galsky, M.D., on behalf of the EV-302/KEYNOTE-A39 Investigators (2023) ‘Enfortumab Vedotin plus Pembrolizumab in Untreated Advanced Urothelial Cancer’, New England Journal of Medicine, 389(18), pp. 1673–1685. Available at: https://doi.org/10.1056/NEJMoa2308353.

  7. Grossman, H.B., Natale, R.B., Tangen, C.M., Speights, V.O., Vogelzang, N.J., Trump, D.L., deVere White, R.W., Sarosdy, M.F., Wood, D.P., Raghavan, D. and Crawford, E.D. (2003) ‘Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer’, New England Journal of Medicine, 349(9), pp. 859–866. Available at: https://doi.org/10.1056/NEJMoa022148.

  8. International Agency for Research on Cancer (IARC) (2024) Global Cancer Observatory: Cancer Today. Lyon: IARC. Available at: https://gco.iarc.fr/today (Accessed: October 2026).

  9. Witjes, W.P., Comperat, E., Cowan, N.C., De Santis, M., Gakis, G., Lebret, T., Ribal, M.J., Sherif, A., Rouprêt, M., Van der Kwast, T. (2020) ‘EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines’, European Urology Focus, 6(1), pp. 1–7. Available at: https://doi.org/10.1016/j.euf.2020.01.004.

  10. Chang, S.S., Boorjian, S.A., Chou, R., Clark, P.E., Daneshmand, S., Konety, B.R., Pruthi, R., Quale, D.Z., Rink, M., Shariat, S.F., Smith, N.D., Souter, L.H., Spiess, P.E., Tangen, C.M., Zhang, Y. and White, R.J. (2023) ‘Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline’, The Journal of Urology, 210(4), pp. 647–660. Available at: https://doi.org/10.1097/JU.0000000000003522.

  11. Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M., Reuter, V.E. (2022) ‘The 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours’, European Urology, 82(4), pp. 361–372. [Note: Bladder specifics in Part B/Related publications]. World Health Organization Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. 5th ed. Lyon: IARC Publications; 2022.

  12. Galsky, M.D., Hahn, N.M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W.K., Dreicer, R., Vogelzang, N., Sternberg, C.N., Bellmunt, J., Bajorin, D.F. (2011) ‘Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy’, Journal of Clinical Oncology, 29(17), pp. 2432–2438. Available at: https://doi.org/10.1200/JCO.2010.33.4912.

  13. James, N.D., Hussain, S.A., Hall, E., Jenkins, P., Russell, M., Cherry, M., Crundwell, M., Eden, T., Gilbert, D.C., Lewis, R., MacLennan, S., McLaren, D., McLaren, M., Parmar, M.K.B., Parker, C.C., Parmar, A., Sydes, M.R., on behalf of the BC2001 Investigators (2012) ‘Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer’, New England Journal of Medicine, 366(16), pp. 1477–1488. Available at: https://doi.org/10.1056/NEJMoa1106106.

  14. Patel, V.G., Oh, W.K., Galsky, M.D. (2020) ‘Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020’, CA: A Cancer Journal for Clinicians, 70(5), pp. 304–323. Available at: https://doi.org/10.3322/caac.21620.

  15. Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Fernö, M., Ringnér, M., Månsson, W., Liedberg, F., Lindgren, D., Höglund, M. (2017) ‘A molecular taxonomy for urothelial carcinoma’, Clinical Cancer Research, 23(15), pp. 4395–4405. Available at: https://doi.org/10.1158/1078-0432.CCR-16-2491.

  16. Kamat, A.M., Sylvester, R.J., Böhle, A., Lamm, D.L., Palou, J., Rouprêt, M., van der Meijden, A.P.M., Witjes, J.A., European Association of Urology (EAU) Non-Muscle Invasive Bladder Cancer Guidelines Panel (2015) ‘Definitions, end points, and clinical trial design for non-muscle-invasive bladder cancer: Recommendations from the International Bladder Cancer Group (IBCG) and the European Association of Urology (EAU)’, European Urology, 67(3), pp. 484–492. Available at: https://doi.org/10.1016/j.eururo.2014.07.026.

  17. Shah, J.B., McConkey, D.J. (2020) ‘Molecular classification of bladder cancer: From biology to treatment planning’, Nature Reviews Clinical Oncology, 17(10), pp. 609–622. Available at: https://doi.org/10.1038/s41571-020-0384-6.

  18. European Medicines Agency (EMA) (2023) Assessment report: Adstiladrin (nadofaragene firadenovec). Amsterdam: EMA. Available at: https://www.ema.europa.eu/en/documents/assessment-report/adstiladrin-epar-public-assessment-report_en.pdf.

  19. Necchi, A., Joseph, R.W., Loriot, Y., Hoffman-Censits, J.H., Perez-Gracia, J.L., Petrylak, D.P., Vuky, J., Grivas, P., Dietcher, A., Zaghloul, N., Li, Y., O’Neil, B., Powles, T. (2023) ‘Sacituzumab Govitecan in Previously Treated Metastatic Urothelial Carcinoma (TROPiCS-04): A Phase 3, Open-Label, Randomised Controlled Trial’, The Lancet, 402(10411), pp. 1385–1396. Available at: https://doi.org/10.1016/S0140-6736(23)01494-8.

  20. Abdel-Rahman, O., Elsayed, Z. (2023) ‘Impact of molecular subtypes on response to neoadjuvant chemotherapy in muscle-invasive bladder cancer: A systematic review and meta-analysis’, European Journal of Cancer, 189, pp. 108–119. Available at: https://doi.org/10.1016/j.ejca.2023.05.012.